Andrea Necchi, MD, Vita-Salute San Raffaele University and IRCCS San Raffaele Hospital and Scientific Institute, Milan, Italy, discusses the effects of a CDH1 mutation on urothelial carcinoma treatment, with research revealing 3.6% of studied patients possessed this mutation. Genomic landscaping suggests these patients have different biomarkers such as less frequency of fibroblast growth factor receptor (FGFR) alteration and higher median tumor mutational burden. Real-world outcomes were investigated by matching two patient databases and comparing clinical outcomes of CDH1 mutated urothelial carcinoma with CDH1 wild-type carcinoma for patients receiving frontline therapy. Research suggests patients with CDH1 mutations respond worse to primary immunotherapy treatments and Dr Necchi suggests primary chemotherapy may be a more appropriate strategy for patients with this form of metastatic disease. This interview took place at the ASCO GU Cancers Symposium 2023 in San Francisco, CA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.